

## **Karolinska Development AB appoints new Chief Financial Officer**

**STOCKHOLM – January 28, 2014. Karolinska Development announced today that Christian Tange has accepted the role of Chief Financial Officer. He will succeed Robin Wright, who will be leaving the company at the end of February, following the audit and report of the 2013 annual results.**

Christian Tange (b. 1966) has over 15 years' experience in international growth companies. In recent years, he has acted as an industrial advisor and consultant for Private Equity funds and Corporate Finance advisors in M&A deals within life science. During the period 2003-2012 he worked as global CFO of CMC Biologics, an international biotech contract manufacturing company. Christian holds a Masters degree in Economics and Law from Copenhagen Business School. He will start working with Karolinska Development from February 1, 2014 and take on the CFO role on March 1, 2014.

"After many years of working in Sweden, Robin Wright has decided to leave Karolinska Development to take up a new role in the UK to be nearer to his family. We understand and respect his decision and we thank him for his significant contributions to the company's progress. At the same time, it is a pleasure to welcome Christian Tange to the CFO position. Christian has a strong track record as CFO and his experience in healthcare M&A and business development matches perfectly with Karolinska Development's current focus. I am looking forward to working with him in future deals", says Torbjörn Bjerke, CEO of Karolinska Development.

### **For further information, please contact:**

Torbjörn Bjerke, CEO, Karolinska Development AB

Phone: +46 (0)72 744 41 23, e-mail: [torbjorn.bjerke@karolinskadevelopment.com](mailto:torbjorn.bjerke@karolinskadevelopment.com)

Benjamin Nordin, IRO, Karolinska Development AB

Phone: +46 (0)73 093 60 80, e-mail: [benjamin.nordin@karolinskadevelopment.com](mailto:benjamin.nordin@karolinskadevelopment.com)

### **TO THE EDITORS**

#### **About Karolinska Development AB**

Karolinska Development aims to create value for patients, researchers, investors and society by developing innovations from world class science into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the greatest return on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products. An exclusive deal flow agreement with Karolinska Institutet Innovations AB, along with other cooperation agreements with leading universities, delivers a continuous flow of innovations. Today, the portfolio consists of 35 projects, of which 16 are in clinical development. For more information, please visit [www.karolinskadevelopment.com](http://www.karolinskadevelopment.com).

*Karolinska Development is listed on NASDAQ OMX. Karolinska Development may be required to disclose the information provided herein pursuant to the Securities Markets Act.*